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PRM13
Data ExtRaction FoR SyStEMatic REviEw – whERE to Look FoR Data 
outSiDE thE PRiMaRy PubLication
Quigley J.M., Halfpenny N.J., Thompson J.C., Scott D.A.
ICON Health Economics, Oxford, UK
Objectives: A common problem in systematic reviews are incomplete data extrac-
tion forms resulting in problems attempting evidence synthesis; we rarely have all 
the data for the endpoints of interest for all studies, and parameters that inform 
meta-analysis or connect networks are missing. Increased transparency in clini-
cal trial reporting means this problem is slowly disappearing. From January 2015 
the European Medicines Agency (EMA) will publish clinical study reports submit-
ted with marketing-authorisation applications for human medicines. MethOds: 
We identified several data sources outside the primary publication. Standard data 
sources for systematic reviews of interventions include peer-reviewed publications, 
conference abstracts and clinical trial registries. Clinical study protocols are often 
published but are not identifiable through searches in online databases, therefore, 
to find these, systematic reviewers must visit the journal website. Manufacturer 
submissions to health regulators are also increasingly made available; these give 
detailed trial descriptions and results presented are more likely to be comprehen-
sive. Results: In a recent example in Hepatitis-C we utilised several additional 
data sources in our evidence synthesis. Clinical trial protocols were used to iden-
tify definitions of endpoints included and to fulfil aspects of the critical appraisal. 
Fibrosis stage is an accepted treatment effect modifier in Hepatitis-C; our review 
therefore collected subgroup data for this. However, this was not readily available 
in peer-reviewed publications; we thus obtained data from EMA submission docu-
ments and UK and German reimbursement submissions. Other examples include a 
2013 COPD systematic review which retrieved mortality data from the FDA website 
for three studies reporting cardiovascular-related death and for one study reporting 
overall death. cOnclusiOns: Systematic reviewers should be aware of additional 
data sources that are publically available. Whilst peer-reviewed data is preferential, 
incorporation of this grey literature into an evidence synthesis could lead to a more 
informed overview of clinical efficacy and thereby healthcare decision making.
PRM15
invEStigation oF RELationShiPS bEtwEEn bioMaRkERS oF PotEntiaL 
haRM anD cigaREttE SMoking MEaSuRES aMong cuRREnt, PaSt, anD 
non-SMokERS baSED on nationaL hEaLth anD nutRition ExaMination 
SuRvEy 2007-2012
Saxena K.1, Liang Q.2, Muhammad-Kah R.2, Sarkar M.2
1Virginia Commonwealth University, Richmond, VA, USA, 2Altria Client Services Inc, Richmond, 
VA, USA
Objectives: Assess the potential relationships between Biomarkers of Potential 
Harm (BOPH), specifically WBC, Apo lipoprotein, C-reactive protein, HDL, LDL, total 
cholesterol, and biomarkers of cigarette smoke exposure (BOE), specifically serum 
cotinine, creatinine adjusted urinary total NNAL and 1-hydroxypyrene (1-OHP), 
using National Health and Nutrition Examination Survey (NHANES) data from 2007 
till 2012. Secondary objective was to assess the relationship between BOPH and 
smoking status (past, current or never), and cigarette per day (CPD) use in current 
smokers. MethOds: Data were obtained from NHANES 2007 to 2012. The study 
sample included 17,293 respondents age 21 years and above who had answered 
questions on cigarette smoking and had complete laboratory values for their bio-
markers measurement. The population was categorized as current (CS), past (PS), 
and never smokers (NS), based on self-reported responses. The exposure variables 
were the BOE, smoking status and CPD. The outcome variables were levels of the 
BOPH listed above. Weighted survey linear regression was used to estimate the 
association between exposure and outcome variables. The models were adjusted for 
age, gender, race and body mass index (BMI). Results: The mean concentrations of 
WBC (1000 cells/uL) in CS, PS and NS were 8.15, 6.97 and 6.82 respectively, and that 
of HDL (mg/dL) were 49.92, 53.23 and 53.53, respectively. A statistically significant 
correlation was observed for WBC and HDL with serum cotinine (R2= 0.133 and 
0.222), Total NNAL (R2= 0.072 and 0.210) and 1-OHP (R2= 0.090 and 0.186). Similarly, 
significant correlations for WBC and C-reactive protein with smoking status 
(R2= 0.060 and 0.101), and for WBC and HDL with CPD (R2= 0.098 and 0.160) were 
observed. cOnclusiOns: Among all the BOPH, the correlation between WBC and 
HDL were significant with all the cigarette smoking measures. This analysis sug-
gests that WBC and HDL would be useful BOPH in studies addressing health risks 
of cigarette smoking.
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coMbining McDa with aDvancED StatiSticS to tackLE chaLLEngES oF 
Data anD JuDgMEnt uncERtainty: caSE StuDy oF SaFEty aSSESSMEntS
Goetghebeur M.M.1, Wagner M.1, Nikodem M.2, Zyla A.2, Micaleff A.3, Amzal B.4
1LASER Analytica, Montreal, QC, Canada, 2LASER Analytica, Krakow, Poland, 3MerckSerono SA, 
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Objectives: Comparative safety assessment can be challenging due to differences 
in safety profiles between comparators, scarcity of data, difficulty in establishing 
causality, and deficiencies in reporting. To address this, a method combining prag-
matic MCDA and advanced statistics was developed and tested by a panel of meth-
odologists and clinical and policy decisionmakers using a case study. MethOds: 
The pragmatic MCDA model categorized adverse events (AEs) generically by their 
clinical consequences into three criteria: ‘non-serious AEs’ (AEs), ‘Non-fatal serious 
AEs’ (SAEs) and ‘Fatal AEs’ (FAEs). Panelists weighted criteria using point allocation. 
Efalizumab for plaque psoriasis, withdrawn in 2009 due to reports of deaths associ-
ated with progressive multifocal leukoencephalopathy (PML), was selected as case 
study. Odds ratios (ORs) for SAEs and AEs were estimated using Bayesian network 
meta-analysis. Incidence of PML was estimated using Poisson modelling. Panelists 
assessed efalizumab safety using a constructed scoring scale for each criterion. 
The approach was re-tested by panelists. Results: Weights for AEs, SAEs and FAEs 
ranged widely between panellist with means (ranges) of 0.06 (0.01-0.1), 0.22 (0.09-
various methods for adjusting confounders in estimating comparative effective-
ness. MethOds: Systematic literature review in PubMed was conducted to iden-
tify published articles with the key words such as propensity score, instrumental 
variable analysis, inverse probability, Propensity Instrumental, Propensity Inverse 
probability, machine learning, support vector machine, CART (Classification And 
Regression Tree) is decision tree learning. Trend analysis was performed by compar-
ing proportions of methods before 2008 and after 2008. Results: 5021 articles were 
found with the key word of comparativeness effectiveness. 227 articles had the key 
word of propensity. 56 articles had the key word of instrumental. 29 articles had the 
key word of inverse probability. 20 articles had key words of both propensity and 
instrumental. 12 articles had key words of both propensity and inverse probability. 6 
articles had key word of machine learning. 6 articles had key word of CART. No article 
was found to have the key word of support vector machine. Overall 6.2% of articles 
had one of the key words, indicating usage of confounder adjustment methods in 
comparative effectiveness research. Two articles had three key words of propensity, 
Inverse probability, and instrumental. Based on Chi-square test, significant increase 
of usage with P-value < .05 in trend has been observed. cOnclusiOns: Based on 
search result, significant increase in usage of confounder adjustment methods was 
observed since 2008. In a few articles, results from a few instrumental variable analy-
ses were conflicting with propensity score method warranting sensitivity analyses 
by employing various methods for adjustment of confounders. Also application 
of machine learning methods is recommended to find stable estimates of models 
used, especially to adjust for time dependent confounders.
PRM11
EvaLuating contEnt vaLiDity oF PERFoRMancE outcoMES (PERFoS): 
EStabLiShing thE PatiEnt-RELEvancE oF thREE PERFoS in ELEctivE totaL 
hiP REPLacEMEnt (EthR)
Ballinger R.S.1, Kerr C.1, Bush E.N.2
1ICON, Oxford, UK, 2Eli Lilly, Indianapolis, IN, USA
Objectives: Performance Outcomes (PerfOs) measure tasks performed by a 
patient under the instruction of a health-care professional. PerfOs used to sup-
port FDA label claims now require content validity evidence. This study explored 
patient experience and relevance of three elective total hip replacement (eTHR) 
PerfOs: the timed up and go (TUG), four step stair climb (4SC) and long stair climb 
(LSC). MethOds: Eight recent eTHR patients in the US were interviewed by tel-
ephone within 7 days of completing three PerfOs. Participants discussed their 
experience of completing the PerfOs; and how the movements, speed and level 
of difficulty corresponded to activities in their everyday lives. Interviews were 
audio-recorded, transcribed and systematically coded. Saturation was assessed by 
tabulated patient summaries from which new elements reported in each interview 
were identified. Results: The sample comprised six females and two males, with 
mean age 67 years. All participants related TUG movements to activities in their 
daily life (e.g. getting up to turn on the television) and most regularly climbed a 
few steps at home and in a similar way to the 4SC (e.g. use of handrail). Climbing 
12 or more steps (LSC) was less common. However, the majority recalled examples 
of this and felt the LSC accurately reflected movement and ability in their replaced 
hip. Two participants reported LSC completion increased their confidence and 
staircase use. Small differences between PerfOs and everyday activities/function 
were reported (e.g. TUG: the type of chair and turning towards rather than away 
from the replaced hip). Assessment of saturation suggested additional interviews 
might yield further varieties in patient experience but that sufficient consensus 
and depth was achieved to understand the relevance of the PerfOs to everyday 
function. cOnclusiOns: New methodological approaches developed to explore 
content validity of PerfOs demonstrate the connection between three PerfOs and 
daily function of eTHR patients.
PRM12
cLinicaL tRiaLS REgiStRiES FoR SyStEMatic REviEwS – an aLtERnativE 
SouRcE FoR unPubLiShED Data
Halfpenny N.J., Thompson J.C., Quigley J.M., Scott D.A.
ICON Health Economics, Oxford, UK
Objectives: When conducting a systematic review it is common practice to search 
for peer-reviewed publications and conference proceedings to identify studies rel-
evant to a research question. However, information about studies is increasingly 
available through other sources and can be of importance in systematic reviews. 
Clinical trials registries (CTRs) are increasingly providing unpublished results of 
studies that can be used in systematic reviews. Clinicaltrials.gov is one of the most 
commonly used CTRs and provides search facilities that enable the identification of 
trials through common search terms. In addition, there is the potential to request 
information from study sponsors through clinicalstudydatarequest.com. This 
website is supported by several prominent study sponsors and allows reviewers to 
request access to unpublished data which may be of importance in a systematic 
review. MethOds: We searched two disease areas (melanoma and juvenile idi-
opathic arthritis (JIA)) for instances where there were discrepancies in reporting 
of endpoints between peer-reviewed publications and the clinicaltrials.gov web-
page for corresponding trials. We submitted requests to clinicalstudyrequest.com 
for additional information on trials in both disease areas. Results: We identified 
additional reporting of subgroups as well as efficacy endpoints in clinicaltrials.gov 
that were not available in peer-reviewed publications. Results included one trial in 
melanoma (METRIC) which reported on only mixed line patients in a peer-reviewed 
publication; results stratified by previous therapy were available from the CTR. In 
addition, results from our search in JIA included additional reporting of efficacy out-
comes such as change in component scores from baseline. We detail length of time 
for response and issues with submission of data requests to clinicalstudyrequests.
com. cOnclusiOns: We conclude that sources other than peer-reviewed articles 
and conference abstracts should be considered when identifying study information 
that may be relevant to a particular review. Unpublished data may be available that 
can impact a systematic review and evidence synthesis.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A13
rankings obtained from standard logistic regression (LR) relative to MLM mod-
eling of risk-adjusted hospital mortality rates for stroke among hospitals in the 
south. MethOds: The 2012 U.S. Nationwide Inpatient Sample (NIS) was used 
to identify patients with a primary diagnosis for ischemic stroke, using ICD-9 
diagnosis criteria. Stepwise backward selection technique with logistic regres-
sion and multilevel modeling was performed to examine the variation among 
hospitals in the south by adjusting for patient-level and hospital-level risk factors. 
The analysis included hospitals with more than 30 stroke cases in the southern 
region of the U.S. The hospital IDs have been masked in order to comply with the 
NIS data user agreement. Results: There were 19,071 stroke hospitalizations in 
320 hospitals. The same rankings were observed for top performers in hospitals’ 
observed/expected ratios (O/E) by LR and MLM. However, high O/E outlier status 
differed between the two statistical methods, yielding different rankings for worst 
performance. Hospital K, L, M were ranked as the worst 3 performers in LR whereas 
K, N, L were ranked the same in MLM. O/Es of Hospital K were 4.49 (CI= 1.62-9.84) 
and 3.942 (CI= 1.42-8.64) in LR and MLM, respectively. O/E’s of Hospital L were 4.24 
(CI= 1.90-8.13) and 3.33 (CI= 0.70-9.54) in LR and MLM, respectively. LR identified 
Hospital M’s O/E ratio as 3.58 (1.47-7.26). MLM identified Hospital N’s O/E as 3.33 
(CI= 0.70-9.54). cOnclusiOns: Although both logistic regression and multilevel 
modeling produced similar rankings for top performers, the MLM approach was 
more conservative in its O/E ratio estimates which were shrunken towards the 
overall mean. The MLM method is recommended to better statistically adjust and 
avoid false positive identification of outliers.
PRM20
coMPaRing thE PREDictivE PERFoRMancE oF two vaRiantS oF thE 
ELixhauSER coMoRbiDity MEaSuRES FoR aLL-cauSE in-hoSPitaL 
MoRtaLity in a LaRgE MuLti-PayER u.S. aDMiniStRativE DatabaSE
Fortin Y.1, Crispo J.1, Emons M.F.2, Mattison D.R.3, Krewski D.1
1University of Ottawa, Ottawa, ON, Canada, 2Cerner Corporation, Culver City, CA, USA, 3Risk 
Sciences International, Ottawa, ON, Canada
Objectives: Tools used to address confounding, such as measures of patient 
comorbidity, should preferably be validated prior to conducting health services 
and outcomes research using novel sources of administrative health data. Our 
objective was to validate and compare the predictive performance of two vari-
ants of the Elixhauser comorbidity measures for predicting all-cause, in-hospital 
mortality using Cerner Health Facts®, a large nationwide U.S. multi-payer elec-
tronic health record database. MethOds: Quan et al. and the AHRQ version 3.7 
adaptations of the Elixhauser comorbidity measures were selected to estimate 
the comorbidity burden of Health Facts® inpatients, outpatients, and emergency 
care recipients aged 18 to 89 years from Jan. 2000 to Dec. 2012. Diagnoses identi-
fied one and two years preceding an index encounter were assessed in a group 
of unique patients. C-statistics obtained from forward stepwise multiple logistic 
regression fitted models and ROC curve differences were derived to compare the 
predictive performance of each variant/lookback period combination. Results: 
Of 8,128,713 patients with a mean age of 51.4 years and a male composition of 
41.6%, 76,235 (0.9%) were deceased at 1-year. Age, sex and all comorbidities were 
significantly correlated with mortality in the two Elixhauser variants irrespec-
tive of lookback period. Excellent predictive performance (c-statistic) was found 
for the Quan (c1yr= 0.874, c2yrs= 0.873) and AHRQ (c1yr= 0.871, c2yrs= 0.870) vari-
ants and both exceeded the baseline model (c= 0.803, P< .0001) limited to age and 
sex. The Quan variant performed slightly better than the AHRQ variant in both 
lookback periods. However, increasing the lookback period from 1 to 2 years did 
not improve predictive performance. cOnclusiOns: Variants of the Elixhauser 
comorbidity measures were validated in Cerner Health Facts® and demonstrated 
excellent predictive performance for all-cause in-hospital mortality at one year. 
These results support the utility of Health Facts® as a novel and attractive source 
of data for administrative database research.
PRM21
StatiSticaL iDEntiFication oF PatiEnt SELEction biaS in 
REtRoSPEctivE chaRt REviEwS
Signorovitch J.E.1, Reichmann W.M.1, Li N.1, Liu Z.2, Hao Y.2, Perez J.R.2
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, 
NJ, USA
Objectives: Retrospective chart reviews are often used to generate real-world evi-
dence of patient outcomes. Physicians participating in these studies may be asked 
to randomly select patient charts for inclusion among all charts meeting eligibility 
criteria. Random selection is important for obtaining representative samples and 
unbiased estimates of patient outcomes. This study examined a statistical method 
for detecting non-random selection of patient charts with an application to real 
data. MethOds: Example data were drawn from a recent retrospective oncology 
chart review study that estimated overall survival (OS) and progression-free survival 
(PFS) following the start of treatment. In the study, participating physicians were 
asked to provide a random sample of their eligible patients. Latent class analysis 
(LCA) was used to test whether the distribution of PFS and OS was consistent with 
random selection for all charts (a one class model) versus a mixture in which some 
physicians selected random charts and others selected non-random, convenient 
charts (models with > 1 class). The best fitting model was identified using infor-
mation criteria. Physician characteristics, PFS and OS were compared across latent 
classes. Results: In overall sample of charts, median durations of OS and PFS 
were significantly longer than published benchmarks drawn from randomized tri-
als. LCA identified evidence for two classes of physicians. One class was consistent 
with biased selection for recently seen patients who were still alive at the time 
of chart review, resulting in bias towards longer OS and PFS. The other class was 
consistent with random selection, and exhibited OS and PFS that were significantly 
closer to published benchmarks. cOnclusiOns: In this example using data from 
a retrospective oncology chart review, LCA was helpful in identifying physicians 
who may have selected convenient but non-random patient charts. LCA warrants 
0.40), and 0.72 (0.50-0.90), respectively, but were stable over time (re-test). For data 
available in 2009, incidence of PML (cases per 100,000 patients) over two years was 
estimated at 0.22 (95% CI 0.00078–3.13) for patients initiated on efalizumab and 
1.21 (0.0052–14.81) for patients remaining on treatment. ORs versus placebo were 
1.7 (1.4–2.2) for AEs and 1.5 (0.6–5.1) for SAEs. Combination of normalized weights 
and scores yielded a safety estimate of efalizumab versus placebo in 2009 of -0.65 
(stdev 0.28) (on a scale of -1 to +1). The same approach was applied to compare 
efalizumab with three active comparators. cOnclusiOns: The method supports 
comparative safety assessment and captures uncertainty in judgments and in data, 
allowing the inclusion of rare, disparate and newly emergent safety data in quan-
titative assessments.
PRM17
LongituDinaL anD cRoSS SEctionaL aSSESSMEntS oF hEaLth utiLity in 
aDuLtS with hiv/aiDS: a SyStEMatic REviEw anD MEta-anaLySiS
Tran B.
Hanoi Medical University, Hanoi, Vietnam
Objectives: Utility estimates are important health outcomes for economic evalua-
tion of care and treatment interventions for patients with HIV/AIDS. We conducted 
a systematic review and meta-analysis of utility measurements to examine the 
performance of preference-based instruments, estimate health utility of patients 
with HIV/AIDS by disease stages, and investigate changes in their health utility over 
the course of antiretroviral treatment. MethOds: We searched PubMed/Medline, 
Cochrane Database of Systematic Review, NHS Economic Evaluation Database and 
Web of Science for English-language peer-reviewed papers published during 2000-
2013. We selected 49 studies that used 3 direct and 6 indirect preference based 
instruments to make a total of 218 utility measurements. Random effect models 
with robust estimation of standard errors and multivariate fractional polynomial 
regression were used to obtain the pooled estimates of utility and model their 
trends. Results: Reliability of direct-preference measures tended to be lower than 
other types of measures. Utility elicited by two of the indirect preference meas-
ures - SF-6D (0.171) and EQ-5D (0.114), and that of Time-Trade off (TTO) (0.151) 
was significantly different than utility elicited by Standard Gamble (SG). Compared 
to asymptomatic HIV patients, symptomatic and AIDS patients reported a decre-
ment of 0.025 (p= 0.40) and 0.176 (p= 0.001) in utility scores, adjusting for method of 
assessment. In longitudinal studies, the pooled health utility of HIV/AIDS patients 
significantly decreased in the first 3 months of treatment, and rapidly increased 
afterwards. Magnitude of change varied depending on the method of assessment 
and length of antiretroviral treatment. cOnclusiOns: The study provides an 
accumulation of evidence on measurement properties of health utility estimates 
that can help inform the selection of instruments for future studies. The pooled 
estimates of health utilities and their trends are useful in economic evaluation and 
policy modelling of HIV/AIDS treatment strategies.
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iMPRoving PaRaMEtER EStiMation FoR a DEciSion-anaLytic MaRkov 
MoDEL to EvaLuatE thE uSE oF novEL bioMaRkER LED StRatEgiES FoR 
PREvEtion oF caRDiovaScuLaR DiSEaSE
Lamrock F.1, Cairns K.1, Kee F.1, Conrads-Frank A.2, Schnell-Inderst P.2, Salomaa V.3, 
Blankenberg S.4, Zeller T.4, Saarela O.5, Kuulasmaa K.3, KÜhne F.2, Siebert U.2
1Queen’s University Belfast, Belfast, UK, 2UMIT - University for Health Sciences, Medical 
Informatics and Technology, Hall i.T., Austria, 3THL - National Institute for Health and Welfare, 
Helsinki, Finland, 4University Health Center Hamburg, Hamburg, Germany, 5McGill University, 
Montreal, QC, Canada
Objectives: This study sought to compare and improve the methods for estimating 
input parameters to populate a decision-analytic Markov model for use in the health 
economic assessment of novel biomarkers for primary prevention of Cardiovascular 
Disease. MethOds: An initial five-state Markov model is built using the FINRISK97 
cohort and follow-up for coronary and stroke events. Two different approaches to 
estimate the transition rates between health states are used. The first approach 
involves a separate analysis for each of the transitions between different health 
states each using a separate Cox Proportional Hazards model (censoring any move-
ments outside the health states of interest). In the second approach, all the transi-
tions are examined in one process using the R package ‘msm’ to maximize the 
overall likelihood expression. Results: The first approach requires considerable 
data manipulation to account for the censoring in each separate analysis; however 
convergence of results is less problematic. While msm considers the overall likeli-
hood expression, it has difficulty fitting a five-state model due to the number of 
parameters which need estimated. Two recommendations from this research for 
using msm include building the model iteratively, adding covariates one step at a 
time. For example to build the model with age plus one covariate, the baseline tran-
sition matrix and regression coefficients from the age only model are used as initial 
guesses. The second recommendation would be to use the regression coefficients 
obtained in the first approach for initial “guesses” of the coefficients in the second 
approach. cOnclusiOns: Parameter estimation for the Markov process within 
decision-analytic Markov models can be obtained from separate sources, but we 
recommend fitting Markov models to one source of longitudinal data. The output for 
the parameter estimates varied between the approaches used, and while msm is a 
useful tool for parameter estimation, it requires reasonable initial approximations.
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Do DiFFEREnt MoDELing tEchniquES changE RankingS oF hoSPitaL 
PERFoRMancE? : MuLtiLEvEL MoDELing vS. StanDaRD LogiStic 
REgRESSion
Yucel A., Ferries E.A., Sharma M., Johnson M., Aparasu R.
University of Houston, Houston, TX, USA
Objectives: There are conflicting results about whether using multilevel mod-
eling (MLM) produces different rankings in hospital performance compared 
to using traditional statistical techniques. We would like to compare hospital 
